NVO Stock Spikes After Record Ozempic Sales—Is It the Perfect Time to Buy Novo Nordisk?

Investors rushed back into Novo Nordisk shares on Wednesday after the Danish drugmaker’s first-quarter 2026 results shattered Wall Street expectations and confirmed blockbuster demand for its new oral weight-loss pill, Wegovy. NVO stock surged more than 7 % in pre-market trade and held most of those gains after the opening bell, reclaiming the psychological $45 level on the NYSE. Management reported that net sales jumped 32 % year over year at constant exchange rates, powered by a “strongest-ever launch” for the GLP-1 Wegovy tablet and continued momentum for injectable Ozempic, its best-selling type-2 diabetes therapy. More than one million prescriptions for the pill were written within the first 90 days on the market, dramatically outpacing early analyst models and triggering a sharp upgrade to full-year guidance. Novo Nordisk now expects 2026 revenue to grow 24 %-30 %, up from 18 %-24 % previously, even after the company baked in a mid-single-digit U.S. price cut meant to fend off Eli Lilly’s rival oral GLP-1 candidate. Chief Executive Lars Fruergaard Jørgensen told investors the early uptake “validates our oral franchise strategy” and gives Novo a multiyear lead in the estimated $100 billion global obesity market. Analysts at Barclays called the pill launch “a game-changer,” noting that production capacity is already being expanded by 50 % to meet surging demand. Trading volume in NVO stock spiked to triple its 30-day average as momentum traders piled in alongside long-term funds repositioning ahead of the company’s mid-June Capital Markets Day. Technical charts show the equity breaking above a two-month downtrend; if bulls defend $45, the next resistance sits near $48, followed by the December peak around $52. Conversely, failure to hold $42 could invite profit-taking back to the 200-day moving average at $39. Beyond the headline numbers, Novo Nordisk booked a DKK 4.2 billion reversal of a prior legal provision, lifting operating margin to 45 %. R&D spend climbed 18 % as management accelerates Phase 3 studies of CagriSema, a once-weekly combination therapy that could reach the market in 2028. While pricing pressure in U.S. Medicare remains a watch-item, most sell-side desks reiterated or raised price targets, with Morgan Stanley moving to $60 (ADR basis) on a 12-month view. Key catalysts over the next quarter include: • FDA decision on a higher-dose Wegovy tablet by late July • Initial obesity data from Lilly’s rival oral orforglipron in June • Supply-chain update on fill-finish expansion at the Clayton, NC facility Bottom line: The Wegovy pill’s record debut, coupled with a guidance hike and capacity expansion, has reignited the growth narrative around NVO stock. With obesity therapeutics still in the early innings and Novo Nordisk holding a first-mover advantage in orals, the path of least resistance for the share price appears higher—provided management can keep supply flowing and pricing intact.